JNJ ▲ +0.1% - Johnson & Johnson $JNJ - Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma 25-SEP-2026 07:00 AM ET